|Awarded On||August 17, 2022|
|Title||Enhancing Cancer Treatment through Direct, Localized, and Sustained Delivery of Therapeutic Agents: Clinical Evaluation in Locally Advanced Pancreatic Cancer|
|Program||Product Development Research|
|Award Mechanism||Company Relocation|
|Institution/Organization||PanTher Therapeutics, Inc|
|Principal Investigator/Program Director||Laura Indolfi|
*Pending contract negotiation
Pancreatic cancer is a highly lethal disease and the third leading cause of cancer death. The only chance for cure remains complete surgical removal, but this is impossible for most patients due to advanced local growth or metastatic spread. For inoperable patients, multiple approaches have been attempted to shrink tumor and allow for subsequent resection. Multiagent chemotherapy is utilized in this "neoadjuvant" approach but has met with limited success due to modest activity and significant side effects. By directly targeting tumors, PanTher's novel approach looks to significantly increase drug accumulation at the site, while dramatically reducing systemic side effects to improve antitumor...